Back

Efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes in older patients: a systematic review and meta-analysis.

25 August 2023 (15:15 - 15:45)
Organised by: Logo
Congress Presentation Part of: Pharmacological therapy in heart failure (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Tomohiro Fujisaki

National Cerebral and Cardiovascular Center Hospital, Osaka (Japan)

5 More presentations in this session

Presentation thumbnail
Torsemide versus furosemide in patients with heart failure: a systematic review and updated meta-analysis of randomised controlled trials
Doctor L. Figueiredo Teixeira (Campina Grande, BR)
Abstract Slides Video
Presentation thumbnail
Modelling clinicians' decisions to adjust loop diuretic dose based on patient-reported symptoms to inform decision-aids in daily care of chronic heart failure
Ms A. Bruninx (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Comparison study of olmesartan and valsartan on myocardial metabolism in patients with dilated cardiomyopathy trial
Professor K. Park (Busan, KR)
Abstract Slides Video
Presentation thumbnail
Differential response to interleukin-1 blockade with anakinra on cardiorespiratory fitness in patients with heart failure with preserved ejection fraction stratified according to ejection fraction
Doctor M. Golino (Jacksonville, US)
Abstract Slides Video
Presentation thumbnail
Sex differences for the efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: a systematic review and meta-analysis.
Doctor T. Fujisaki (Osaka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacological therapy in heart failure (1)

The Event

Event poster

ESC Congress 2023

25 August 2023 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population
thumbnail
Congress Presentation
Sex differences for the efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: a systematic review and meta-analysis.
thumbnail
Congress Presentation
Unlocking SGLT2 inhibitors: evaluating elderly HFrEF patients with and without T2DM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources